0
Last April, HIPRA presented RHINISENG®, the innovative vaccine for the prevention of Progressive and Non- progressive Swine Atrophic Rhinitis, in China. RHINISENG® also offers the perfect balance between safety and efficacy thanks to its exclusive new-generation ginsenoside-based adjuvant (HIPRAMUNE® Gd).
For the occasion, HIPRA brought together four national and international experts in pig production: Dr. Guangzhi Tong (China), Dr. Fangzhen Wu (China), Dr. Enric Marco (Spain) and Dr. Marten de Jong (Holland). Specialists from throughout the country attended the event, which gave them the opportunity to update their knowledge on future developments and trends in pig production in China and internationally, as well as on the control of different diseases, keeping the focus on Atrophic Rhinitis. The RHINISENG® logo, sculpted in ice, closed the event which was co-ordinated by Rong Yu Zeng (Technical and Marketing Manager, HIPRA CHINA) and attended by Rafael Pedrazuela (Swine Business Unit Manager) and Alba Martos (Rhiniseng® Product Manager).
With the launch of RHINISENG® in China, HIPRA is continuing its global expansion and consolidation, specifically on the continent of Asia, as the reference in prevention for animal health.
July 9, 2015 - Hipra
